Keyphrases
Recent Advances
100%
Phosphatidylinositol 3-kinase Inhibitor
100%
Glioblastoma multiforme
100%
Clinical Development
100%
Preclinical Development
100%
Phosphoinositide 3-kinase (PI3K)
62%
Primary Tumor
12%
Hematological Malignancies
12%
Clinical Trials
12%
Synergism
12%
Solid Tumors
12%
Hyperactivity
12%
Central Nervous System
12%
Angiogenesis
12%
Tumor Growth
12%
Tumor Cell Proliferation
12%
Motility
12%
Related Pathway
12%
Kinase Isoform
12%
Methylation Status
12%
Patient Prognosis
12%
Phase III Clinical Trial
12%
Molecular Targeted Therapy
12%
MTOR Inhibitor
12%
MGMT Promoter Methylation
12%
Isoform Selectivity
12%
Tumor Metabolism
12%
Temozolomide
12%
DNA Alkylating Agent
12%
Tumor Cell Survival
12%
Pharmacology, Toxicology and Pharmaceutical Science
Phosphatidylinositol 3 Kinase Inhibitor
100%
Glioblastoma
100%
Phosphatidylinositol 3 Kinase
62%
Clinical Trial
25%
Synergism
12%
Clinical Study
12%
Antiinfective Agent
12%
Tumor Growth
12%
Hematologic Malignancy
12%
Solid Malignant Neoplasm
12%
Temozolomide
12%
Alkylating Agent
12%
Mammalian Target of Rapamycin Inhibitor
12%
Neoplasm
12%
Primary Tumor
12%